ba3021
mAbexperimentalADC
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 12, 2021 (NCT04918186)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Payload
- Monomethyl auristatin E
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095285 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05271604 | Phase 2 | Oct 31, 2022 | BioAtla, LLC |
| NCT04918186 | Phase 2 | Oct 12, 2021 | AstraZeneca, BioAtla, LLC, British Columbia Cancer Agency, Canadian Cancer Trials Group, Cancer Research Institute, University of Toronto |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioAtla, LLC | For profit | 2 | 1 | 1 | 2021 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2021 |
| British Columbia Cancer Agency | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1